

Global Resource Estimation

Roy Ward, Novartis Pharmaceuticals, Basel, Switzerland

ABSTRACT

The purpose of this paper is to propose methods to control Global Resource needs. This also considers off-shored work and out-sourced work. The considers the need for a "Clinical Study/Project Management Database" where all "Study/Project" event data is stored. Discussion then turns toward the need to have trial/project life cycle stage algorithms which can produce a "First Shot Default Estimate" for trial and project level estimates. Once the "First Shot Default Estimate" is produced we consider adjusting these figures to accommodate for know deviations from the algorithms, "savings due to outsourcing" is also considered at this point. Once we have resource estimates at the Brand level we then consider the resource estimates as a TA. Given we have a statistic for the resource estimate we can then consider what our "gap" is by creating a statistic for how many resources we have on board.

As a final "reality check" and to ensure the projects remain adequately resourced we consider "bottom-up" estimates and also methods to ensure resources are smoothly allocated for the forthcoming six months.

INTRODUCTION

The introduction explains the purpose and scope of your paper and provides readers with any general information they need to understand your paper.

The world of resource estimation is often a mysterious and bizarre combination of algorithms, guesstimates or just plain "get what you are given". However in today's world where "justification" is king we need to be able to prove to our seniors why we need these extra folk. No-one has the complete correct answer but we must strive to find understandable logic in order to obtain sufficient resourcing.

This paper is designed to give some thought as to several method's in how resource calculations are dealt with within the statistical and programming groups of Novartis pharmaceuticals. Additional "challenges" are considered such as factoring in "outsourcing", "dealing with off-shoring contributions", "modeling Japanese workload", "non-clinical project work" and modeling the inevitable "unplanned events".

CLINICAL STUDY/PROJECT MANAGEMENT DATABASE.

It is imperative that the company as whole has a central database where relevant information is stored regarding to a project. This information is then used by the whole of the companies planning units in determining resourcing and costs for study/project conduct. Information such as Project Name, Study Name, First Patient First Visit(FPFV), Last Patient Last Visit(LPLV), Database Lock(DBL), number of patients and complexity factor(CF) should be in this database. Naturally all studies and projects have different levels of difficulties and four categories are given and these are split into the following four CF's

- i) LOW,
- ii) MEDIUM,
- iii) HIGH
- iv) MEGA(study has +3,000 patients).

For example a study allocated a LOW CF is a study which is a replica of already completed studies in which we already have programs written.

MEDIUM would be a new challenging study and HIGH would be a new study which contains very complex statistical analysis or deals with lots of non-standard work.

A MEGA trial is a study which has over 3,000 patients, usually lasts over a great length of time, contains many variables and naturally spawns many analysis and sub-populations etc....

This database then is highly important in driving how many resources we allocate and also how much budget is required to run the study/project. As we all know the analysis produced from data is only as good as the accuracy of the data in the database so it is vital that this information is kept up to date (otherwise you may not get any resources or money!). The responsibility of this accuracy of the database is left to the Clinical Trial Team (CTT) or more importantly the Clinical Trial Leader (CTL) Note:: Responsibility does not mean physically doing but the person who should ensure the task is completed.

FIRST SHOT DEFAULT ESTIMATES.

So far we have only discussed the storage of relevant clinical trial/project management data. Now we need to introduce a “first shot default estimate”. These can be estimated based on a set of algorithms and assumptions. The algorithms are described below in the following sections. When information is downloaded from this database the algorithms are executed. One must note that these algorithms work on the basis of a start and end date of a period in the life cycle of the trial/project. This figure is then adjusted for the year in question. Generally speaking this is fine since most life cycle stages are less than a year – however we must remember this assumption when considering project level life cycle stages which do span more than a year or when we are dealing with mega-trials or Oncology trials which can span 10 years or more.

Trial/Study Level.

Table 1

In-house work	time unit	SR_BU				
Study type		ECD	CRD			
B&SR Complexity Factor			Low or Ph 1	Medium	High	Mega
Multiplication factor			0.75	1	1.5	4
Planning	wd		A1	A2	A3	A4
if ASD	wd					
Execution	wd		B1	B2	B3	B4
if n IAs (n>=1), not SAD	wd		C1	C2	C3	C4
if ASD	wd		n.a.	n.a.		
Reporting	wd		D1	D2	D3	D4
if ASD	wd					

“First Shot Default Estimates” are obtained from the table above. The top columns(second row) define the CF as discussed in the “Clinical Study Database Management Database” section. The rows determine the stage in the life cycle of a study. In Novartis we split the life cycle up into four parts.

Planning – This includes events in the time period from “protocol summary” to FPFV. Naturally this is more resource intensive for our statistical colleagues as this mostly includes the setting up of the study. Statistical Programmers are involved however in tasks such as

- i) input to Database Quality checks to be performed by Data Management colleagues
- ii) matching the CRF to the protocol.

Execution – This is a big chunk of statistical reporting resources. This is the time period from FPFV to DBL. In this time time period the statistical programmer is highly involved with the team in

- i) finalizing the report specifications,
- ii) Creating analysis datasets.
- iii) Creating output deliverables as specified in the report specifications.
- iv) Validating analysis datasets and output deliverables.
- v) dry runs
- vi) implement approved changes to outputs.
- vii) transfer data from the database to our statistical reporting system.

Reporting –This also requires a big chunk of statistical reporting resources and covers the time from DBL to Clinical Trial Report in Report Depository. The Statistical Programmer is involved in the following tasks.

- i) Final Data Transfer.
- ii) Deliver all outputs to CTT.
- iii) Re-perform validation.
- iv) Create CRT's
- v) Ensure we are “audit ready”.
- vi) Implement approved ad-hoc requests.

For sensitivity reasons the true numbers in the table have been replaced by characters. However I am sure one can gather that x_3 would be greater than x_1 where $x = A, B, C, D$.

These algorithms are then coded into a system which refers to the Clinical Study Project Management Database. Using this system the algorithms are executed for each study and a resource “First Shot Default Estimate” is given.

Project Level

As with trial level we can also create resource guesstimates for the project level. Given “project level needs” are much more subject to variation these are more trickier to predict with a set of rigid equations. However we must attempt to model these resource needs.

Table 2

In-house work	Load Distribution	time unit	SR_B U				
B&SR Complexity Factor			Very Low	Low	Medium	High	Very High
Multiplication factor f			0.25	0.5	1	2	3
Early Development (from 50 weeks prior to start of phase I to FDP)	linear	wd/year	A1	A2	A3	A4	A5
Full Development (from FDP to DRA submission)	48-26-26	wd/year	B1	B2	B3	B4	B5
Clinical Submission (1 year prior to DRA submission)	linear	wd	C1	C2	C3	C4	C5
if Population PK		wd					
Clinical post-submission activities (DRA submission to 1 year after DRA submission)	linear	wd	D1	D2	D3	D4	D5
Phase IV (from DRA submission to 5 years post launch, i.e. lag time of 1 year)	67-33	wd/year	E1	E2	E3	E4	E5

For the project level we consider a 5 level CF. Very low being for example a new indication of an already registered drug with minimal extra work at the project level whereas “very high” could be in-licencing a large project which does not follow our standards and the need to merge existing data with standard data.

We consider projects to have a 5 stage life cycle.

Early Development - when the project is in phase I and therefore contains very little project level work for the statistical programmer.

Full Development - the stage where the project enters phase II work right up to DRA submission. Naturally this takes a reasonable level of statistical programming resources for the project level.

Clinical Submission - one year before DRA submission right up to submission time. This is counted as additional resourcing to the Full Development. This is arguably the most resource intensive period of the project life cycle as I am anyone who has experienced would agree. This stage contains the Summary of Clinical Safety(SCS) the Summary of Clinical Efficacy(SCE), ad submission related activities such as Health Authority visits and Briefing Book preparation. Hence this is a major time for pooling activities which naturally become challenging if standards have not been used throughout the project.

Clinical Post-Submission – also require a large amount of resources and are very intense periods of work. This involves Health Authority and FDA questions. If the project has “challenges” this again can inflate the requests.

Phase IV – one year after DRA submission up to five years post launch. One would hope that Health Authority questions would have receded by this point. However publication work should be in full swing at this time point

and also support Key Opinion Leader (KOL) questions comes play. Phase IV study level work should be considered at the trial level and not at this level.

So now from our Clinical Study Project Management Database and associated algorithms we have achieved a “First Shot Default Estimate”.

ADJUSTING FIRST SHOT DEFAULT ESTIMATE ADDING THE “FUDGE FACTOR” AND GETTING A GOOD ESTIMATE FOR THE ENTIRE PROJECT

Although it would be wonderful to assume our “First Shot Default Estimates” are 100% accurate no-one is foolish enough to believe this is true (or are they?). So these estimates need to be adjusted or as sometimes I call it “add the fudge factor”. To do this one has to have good first hand knowledge of the trials or projects or know someone who has this knowledge. From my experience, the “trial level” estimates are very accurate and very rarely need changing. The project level estimates are less reliable and they carry more weight/resources so generally speaking this is the area where we need to pay more attention when considering the good old “fudge factor”. Working very closely with Statistical colleagues changes are made.

Table 3

Brand	Study No.	Description	FPFV	DB Lock	Japan?	First Shot Default Estimate	SR GH adjusted	OPX2 outsourced Y= flag in OPX2, N= flag missing	B&SR comment	Outsourcing 2006
Trial level total						0.33	0.00			
Project level total						0.00	0.00			
Project total						0.33	0.00			
A	B	1301	Z	30 Jun 03	17 Jun 04	J	0.00			
A	B	1303	Z	06 Mar 06	09 Jan 07	J	0.13	0.13	Y	Outsource (decision as to J CRD or staffing model is pending)
A	B	1301EX1	Z	26 Mar 06	09 Jan 08	J	0.17	0.17	Y	Outsource (decision as to J CRD or staffing model is pending)
A	B	2303	Z	01 Nov 06	26 Sep 07		0.32	0.32		
20	A	B	2404	Z	10 Mar 03	09 Sep 06		0.16	0.16	Y=as staffing model - now NISCI
22	A	B	2406	Z	27 Feb 06	31 Mar 07		0.13	0.13	Y
22	A	B	2406EX1	Z	19 Jun 06	31 Mar 07		0.17	0.17	Y
Trial level total						1.08	1.08			
Project level total						0.19	0.69			
Project total						1.27	1.77			
c	c		c				0.00		Y	

The above EXCEL table is resource table shared between Statistics and Statistical programming. This is where adjustments are made. Naturally “Brand”, “Study No.” and “Description” have been changed to protect sensitive information (and protect the guilty!). FPFV, DBL and “First Shot Default Estimate” are transferred directly from our download performed earlier. “Japan” indicates if this study is conducted in Japan hence 1303 is a Japanese study. Hence study 1303 is a Japanese study with FPFV “6 March 2006” DBLock “9 Jan 2007” and has a linear resource estimate for 2007 of “0.13”. On discussion with relevant parties we have no reason to doubt this figure so we do not adjust the figure and transfer to the next column “SR GH adjusted”. However we have chosen to outsource this study so the Outsourced flag is set to Y. This results in a “savings” of resources for Statistical Programming of

0.07. (figure obtained by multiplying the resource estimate by the savings estimate. Relevant information is then added to the "B&SR comment" page which may help understand the trial or decisions about the trial at a quick glance. This process is then repeated for all studies within the project. The sum of resource needs at the trial level for a project is then calculated automatically and can be seen here as 1.08. Hence for Project A the sum of resources needed for 2007 at the trial level is 1.08.

Table 4

Project	Complexity factor	Activity	SR FTEs OPX2	SR FTEs adjusted	BIOS FTEs OPX2	BIOS FTEs adjusted	Remarks
2007 CVM		Total CVM project resources needed	15.05	13.01	23.21	17.34	N.B. Figures in red against project deviate from OPX2 algorithm
		FTEs	20.07	17.35	30.95	23.12	
		Headcount					
B	Low	Full development: project	0	0	0	0	
		Clinical submission preparation, SCS/SCE Japan/China	0	0.5		0.38	Submission in Dec 07.
		Clinical post-submission J /China	0	0	0	0	
		Ph IV/publications	0.19	0.19	0.24	0.24	Limited ph IV
		Total	0.19	0.69	0.24	0.62	
C	Low	Full Development: Proj.team	0	0	0	0	
		Clinical submission preparation, SCS/SCE US	0	0	0	0	
		Clinical submission preparation, SCS/SCE EU	0	0	0	0	
		Clinical post-submission US	0	0	0	0	
		Clinical post-submission EU	0	0	0	0	
		Ph IV/publications	0	0.05	0	0.17	Limited ph IV / post-submission activities?
		Total	0	0.05	0	0.17	
		OPX2	0.72		0.99		
D	Low	Full Development: Proj.team, HA discussions	0.26	0	0.47	0	Initial therapy. Submission Dec 2006
		Clinical submission preparation, SCS/SCE	0.25	0	0.21	0	Single trial submission
		Clinical post-submission	0.34	0.34	0.4	0.4	
		Ph IV/publications	0.53	0	0.67	0	No ph IV activity expected.
		Total	1.38	0.34	1.75	0.4	
		OPX2	0.25		0.53		
		Phase IV overview and review of local protocols	0.93	0.05	1.18	0.1	Redundant. No submission activity expected

Within the same EXCEL spreadsheet we have a second TAB. This TAB deals with Project level resourcing. With reference to table 4 and project B we see that our “First Shot Default Estimate” gives us no resources for “Clinical Submission” However we know we have a Japanese submission in 2007 and therefore we adjust this estimate to an estimate consistent with our algorithm. Hence our underlying Clinical Trial/Project Management Database is NOT sensitive enough to pick this information up. Hence our decision to “review” is justified. So our total resource estimates for project B at the project level is 0.69.

The TAB is table 4 is dynamically linked to the TAB in table 3 hence if we look into table 3 at project B we and look at the project level resources we find our 0.69 estimate. A simple addition then finds that for Project B Total resources required for 2007 “Linearly” are Trial + Project total = 1.08+0.69=1.77

OBTAINING AN ESTIMATE OF RESOURCING REQUIRED FOR THE WHOLE TA

So now we have the information for all the individual projects within the TA.

A simple summation should do the trick to give us the TA total – but we still have work to do...

Table 5

Microsoft Excel - CVM B&SR Resource needs 2006_Jul 06.xls

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z	AA
1				Stat: #####																							
2																											
3																											
4																											
5																											
6																											
7																											
8																											
328																											
329																											
330																											
331																											
332																											
333																											
334																											
335																											
336																											
337																											
338																											
339																											
340																											
341																											

Ready

Table 5 is the summation of all the project totals (again numbers have been changed to protect the guilty). So we see here that our "First Shot Default Estimates" are 100 resources but following our adjustment we believe 99 are required. Now Full Time Employees (FTE) assume that a person is constantly working on this initiative which naturally is not true. Employees take holidays and work on Non-Clinical Projects amongst other things so this figure is inflated by 33%. Hence the number of employees required for our TA's work for 2007 is 132. We have some other calculations which now come into play. Recall our adjustments for outsourcing? This figure is also summed too and in this example is a figure of 1.33. Hence we "save" 1.33 internal headcount resources for 2007 due to outsourcing activities. Wait we are still not finished! Recall our Japanese studies? We also sum these to find that we need 1.27 headcount in Japan for our Japanese work.

So this figure gives us a very good estimate for how many global resources we need.

CALCULATING THE GAP.

So now we know how many people we need – but how many have we got? We need a method to consider all of our global resources including off-shoring. Off-shoring resources do contribute to our resource pool and we cannot consider these resources to be unitary equal to the resources we have in the central unit. So a ratio is applied to adjust for this.

Table 6

Project	Study Level estimate (2005 FTE)	Study Level estimate (2005 FTE)	FTE estimate (2005 FTE)	FTE savings after outsourcing	RESEARCH IT Study Level estimate (2005 FTE)	RESEARCH IT Study Level estimate (2005 FTE)	Allocated Efficiency	Allocated Safety (Central + HCCU, allocated)	Allocated SR	Gap (Study Level estimate - FTE)	Gap (Study Level estimate - FTE)
28	19.73	7.24	16.94	2.44	25.63	24.65	3.79	7.64	16.34	14.85	11.61
29											
30											
31											
32											
33											
34											
35											
36											
37											
38											
39											
40											
41											
42											
43											
44											
45											
46											
47											
48											
49											
50											
51											
52											
53											
54											
55											
56											
57											
58											
59											
60											
61											
62											
63											
CVM	19.97	11.77	11.74	3.74	42.32	17.33	19.66	14.64	24.25	8.02	3.04

Table 6 shows the front TAB of second EXCEL spreadsheet which will help us identify our gap. If we continue we our example of Project B we can identify figures we have seen earlier..

Study Level Estimates = 1.08

Project Level Estimates = 0.69

FTE = 1.77

From table 3 we can also confirm our "resource savings due to outsourcing" for this project is 0.41.

The adjusted FTE figure to give us true Headcount is 2.36.

So the true Headcount I need for this project is the Headcount figure minus my outsourcing savings which is $(1.77 - .41) * 1.33 = 1.81$

So the true number of physical headcount I need for this project is 1.81 people.

Hence this confirms our earlier calculations and is a good cross-check/validation that our figures are correct.

Table 8

	September	October	November	December	January
A					
B	90	95	50	90	
C	105	90	55	70	50
D	150				
E	100	100	100	100	
F	95	105	135	125	95
G	100	150	130	150	
H					
I					
J	160	130	80	30	20
K	100	100	100	100	
L	95	80	100	75	
M	75	55	53	65	
N	125	60	60	70	
O					
P	125	100	100	110	110
Q	95	25	15	25	
R	100	90	110	110	
S	85	75	70	80	
T	115	100	85	105	85
U	100	100	105	115	50

In first column of Table 8 we see the name of the statistical programmer. Across the remaining rows are the %programmer resource required in order to complete deliverables for that month. In this table it is important for programmers to put what resources they personally require and NOT what resources they can give. Hence an ideal situation would be a row of 100's. However in reality that is almost certainly not going to happen. Areas for attention are when a monthly resource exceeds 130 such as programmer J in Spetember or where the programmer exceeds 100 for a period of time such as programmer G. Naturally those programmers who are scoring less than 100 are "options" to place new work to. One word of caution with this method is that generally in month 5 or 6 we see scores of less than 100. In reality this usually does not happen since porogrammers are not modeling in unexpected work.

CONCLUSION

Sound logic is required to calculate resource needs and identify gaps in resourcing. "Gut feeling" is often a very good indicator of resource requirements but it will often not "win" extra resources from management and may mask highly performing and underperforming team. The recommendation is that a "Top Down" approach based on algorithms is applied but is also cross-checked against a "bottom-up" approach of a resource guesstimate from the Program Programmer. References (header 1)

ACKNOWLEDGMENTS (HEADER 1)

Acknowledgments go after your references. This section is not required.

I would like to thank Roger Heath, Margaret McAlary and Mark Thurston for introducing me to most of the concepts and tools discussed in this paper. Additionally I would like to thank Ueli Gugerli for supplying me with the algorithms.

CONTACT INFORMATION (HEADER 1)

Roy Ward
Novartis Pharmaceuticals
Statistical Reporting Group Head for CVM
B&SR
CH-4002

PhUSE 2006

Basel
Switzerland

Roy.Ward@Novartis.com

SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.

Other brand and product names are trademarks of their respective companies.

Other brand and product names are trademarks of their respective companies.